AlloMune system

AlloMune™ system

A proprietary system designed to re-educate a recipient's immune system to accept a transplanted organ as its own, which is based on transplanting bone marrow (BM) from donor to recipient to establish mixed BM chimerism, allowing the recipient's body to recognise a donor organ as its own without needing long-term anti-rejection therapy.

The AlloMune system included conditioning of the recipient and treatment with MEDI-507 and enriched peripheral blood progenitor cells; post-transplant, patients are placed on short-term immunosuppressive therapy.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
- Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
In addition, the company is developing the AlloMune System, which is designed to treat a variety of hematologic malignancies, and its distribution partner Gambro BCT markets the Eligix(TM) family of cell separation products in Europe for use in bone marrow, stem cell and donor leukocyte transplants.
In late July BioTransplant announced it was implementing a restructuring plan intended to streamline the company's operations around its most promising proprietary products-the Allomune System and Eligix HDM Cell Separation technologies.
In the studies, miniature swine received a prototype of BioTransplant's AlloMune System and a 30 to 60 day course of cyclosporin as conditioning for a high-dose peripheral blood stem cell (PBSC) transplant from haploidentical donors.
Elliot Lebowitz, PhD, BioTransplant's President and CEO said, "Our AlloMune System for Cancer utilizes a number of advanced approaches designed to facilitate the acceptance of donor cells and tissue by the human immune system.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
The AlloMune System is designed to allow long-term organ acceptance without the use of chronic immunosuppressive drugs.